Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

医学 安慰剂 依达拉奉 肌萎缩侧索硬化 内科学 物理医学与康复 多发性硬化 双盲 麻醉 疾病 精神科 病理 替代医学
作者
Koji Abe,Masashi Aoki,Shoji Tsuji,Yasuto Itoyama,Gen Sobue,Masanori Togo,Chikuma Hamada,Masahiko Tanaka,Makoto Akimoto,Kazue Nakamura,Fumihiro Takahashi,Kazuoki Kondo,Hiide Yoshino,Koji Abe,Masashi Aoki,Shoji Tsuji,Yasuto Itoyama,Gen Sobue,Masanori Togo,Chikuma Hamada
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (7): 505-512 被引量:813
标识
DOI:10.1016/s1474-4422(17)30115-1
摘要

Summary

Background

In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population. We aimed to substantiate this post-hoc result and assess safety and efficacy of edaravone in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc analysis inclusion criteria.

Methods

In this phase 3, randomised, double-blind, parallel-group study, patients aged 20–75 years with ALS of grade 1 or 2 in the Japan ALS Severity Classification, scores of at least 2 points on all 12 items of ALSFRS-R, forced vital capacity of 80% or more, definite or probable ALS according to the revised El Escorial criteria, and disease duration of 2 years or less were recruited from 31 hospitals in Japan. Eligible patients also had a decrease of 1–4 points in the ALSFRS-R score during a 12-week observation period before randomisation. Patients meeting all criteria were then randomly assigned 1:1 to receive 60 mg intravenous edaravone or intravenous saline placebo for 6 cycles (4 weeks per cycle with 2 weeks on, 2 weeks off) for a total treatment duration of 24 weeks. In cycle 1, the study drug or placebo was administered once per day for 14 days within a 14 day period, followed by the drug-free period. In cycle 2 and thereafter, the study drug or placebo was administered for 10 days within a 14 day period, followed by a 2 week drug-free period. Participants and investigators, including those assessing outcomes, were masked to treatment allocation. The primary efficacy outcome was the change in ALSFRS-R score from the baseline to 24 weeks (or at discontinuation if this was after the third cycle) after randomisation. The primary outcome was assessed in all patients who had received at least one treatment infusion, had at least one assessment post-baseline, and reached the end of cycle 3. For patients with missing values at the end of cycle 6, data were imputed by the last observation carried forward (LOCF) method, provided the patients had completed at least cycle 3. Safety was assessed in all patients who had received at least one treatment infusion and had at least one assessment post-baseline. This trial is registered with ClinicalTrials.gov, NCT01492686.

Findings

Between Nov 28, 2011, and Sept 3, 2014, we screened 213 patients, and enrolled 192 as potential participants. Of these, 137 patients completed the observation period: 69 were randomly assigned to receive edaravone, and 68 were randomly assigned to receive placebo. 68 patients taking edaravone and 66 taking placebo were included in the primary efficacy analysis. For the primary outcome, the change in ALSFRS-R score was −5·01 (SE 0·64) in the edavarone group and −7·50 (0·66) in the placebo group. The least-squares mean difference between groups was 2·49 (SE 0·76, 95% CI 0·99–3·98; p=0·0013) in favour of edaravone. Treatment-emergent adverse events were reported in 58 (84%) patients receiving edaravone and 57 (84%) patients receiving placebo. 11 (16%) patients taking edaravone and 16 (24%) taking placebo had serious adverse events, and one (1%) patient receiving edaravone and four (6%) patients receiving placebo had adverse events (one dysphagia in edaravone group and one dyspnoea, two respiratory disorder, and one rash in the placebo group) that led to withdrawal.

Interpretation

Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo. There is no indication that edaravone might be effective in a wider population of patients with ALS who do not meet the criteria.

Funding

Mitsubishi Tanabe Pharma Corporation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XZY发布了新的文献求助10
刚刚
可乐冰淇淋完成签到,获得积分10
1秒前
3秒前
3秒前
Ljc发布了新的文献求助10
3秒前
4秒前
5秒前
大海风完成签到,获得积分10
6秒前
奥特波顿发布了新的文献求助10
7秒前
刘丽梅完成签到 ,获得积分10
9秒前
9秒前
wangdanli完成签到,获得积分10
10秒前
11秒前
12秒前
12秒前
x1981完成签到,获得积分10
13秒前
小西完成签到 ,获得积分10
13秒前
嘻哈发布了新的文献求助10
13秒前
14秒前
Billy发布了新的文献求助10
14秒前
16秒前
16秒前
奥特波顿完成签到,获得积分10
17秒前
刘Liam完成签到 ,获得积分10
18秒前
无花果应助wangdanli采纳,获得10
18秒前
吱吱发布了新的文献求助10
19秒前
FashionBoy应助糊涂的猎豹采纳,获得30
19秒前
wtt发布了新的文献求助10
19秒前
20秒前
哈哈哈哈发布了新的文献求助10
21秒前
22秒前
23秒前
852应助RNAPW采纳,获得10
23秒前
嘎嘎嘎完成签到,获得积分10
23秒前
24秒前
123完成签到,获得积分20
25秒前
沉默初雪发布了新的文献求助10
26秒前
今后应助paixxxxx采纳,获得10
27秒前
27秒前
CC悟了发布了新的文献求助10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975661
求助须知:如何正确求助?哪些是违规求助? 3520000
关于积分的说明 11200535
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390